Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism
- PMID: 20971371
- DOI: 10.1016/j.joms.2010.07.017
Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism
Abstract
Purpose: Osteonecrosis of the jaw has been reported in patients receiving high doses of intravenous nitrogen-containing bisphosphonates (N-BPs) because of malignant disease. The exact pathomechanisms have been elusive and questions of paramount importance remain unanswered. Recent studies have indicated toxic effects of bisphosphonates on different cell types, apart from osteoclast inhibition. Multipotent stem cells play an important role in the processes of wound healing and bone regeneration, which seem to be especially impaired in the jaws of patients receiving high doses of N-BPs. Therefore, the aim of the present study was to investigate the effects of different bisphosphonate derivatives and dose levels combined with varying pH levels on the mesenchymal stem cells in vitro.
Materials and methods: The effect of 2 N-BPs (zoledronate and ibandronate) and 1 non-N-BP (clodronate) on immortalized mesenchymal stem cells was tested at different concentrations, reflecting 1, 3, and 6 months and 1, 3, 5, and 10 years of exposure to standard oncology doses of the 2 N-BPs and equimolar concentrations of clodronate at different pH values (7.4, 7.0, 6.7, and 6.3). Cell viability and activity were analyzed using a WST assay. Cell motility was investigated using scratch wound assays and visualized using time-lapse microscopy.
Results: Both types of bisphosphonates revealed remarkable differences. Zoledronate and ibandronate showed a dose- and pH-dependent cellular toxicity. Increasing concentrations of both N-BPs and an acidic milieu led to a significant decrease in cell viability and activity (P < .01), with more pronounced effects for zoledronate. Equimolar concentrations of clodronate did not affect the cell survival or activity significantly, apart from the effect of pH reduction itself, which was also detectable in the patients in the control group who did not receive bisphosphonates.
Conclusions: Our results have shown that high concentrations of N-BPs and a local acidic milieu, which is commonly present in infections of the jaw, might play a key role in the pathogenesis of osteonecrosis of the jaw in patients receiving high doses of N-BPs for malignant diseases. Also the potency of N-BPs might be different, suggesting a greater risk of osteonecrosis of the jaw with zoledronate.
Copyright © 2010 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Bisphosphonate-related osteonecrosis of the jaw: is pH the missing part in the pathogenesis puzzle?J Oral Maxillofac Surg. 2010 May;68(5):1158-61. doi: 10.1016/j.joms.2009.07.079. J Oral Maxillofac Surg. 2010. PMID: 20138420 Review.
-
Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.Oral Oncol. 2008 Sep;44(9):857-69. doi: 10.1016/j.oraloncology.2007.11.012. Epub 2008 Feb 20. Oral Oncol. 2008. PMID: 18282788
-
[Bisphosphonates and osteonecrosis of the jaws in patients with myelomatosis].Ugeskr Laeger. 2006 May 22;168(21):2078-9. Ugeskr Laeger. 2006. PMID: 16768928 Danish.
-
The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study.Clin Oral Investig. 2012 Feb;16(1):87-93. doi: 10.1007/s00784-010-0507-6. Epub 2011 Jan 12. Clin Oral Investig. 2012. PMID: 21225298
-
A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.Clin Ther. 2007 Aug;29(8):1548-58. doi: 10.1016/j.clinthera.2007.08.008. Clin Ther. 2007. PMID: 17919538 Review.
Cited by
-
Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals.Support Care Cancer. 2020 Sep;28(9):4019-4029. doi: 10.1007/s00520-020-05440-x. Epub 2020 Apr 19. Support Care Cancer. 2020. PMID: 32307659 Free PMC article. Review.
-
Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ).Medicina (Kaunas). 2021 May 9;57(5):463. doi: 10.3390/medicina57050463. Medicina (Kaunas). 2021. PMID: 34065104 Free PMC article. Review.
-
Medication-related osteonecrosis of the jaw (MRONJ) and eNOS Polymorphisms in multiple myeloma patients: a single center experience.BMC Oral Health. 2021 May 18;21(1):272. doi: 10.1186/s12903-021-01634-9. BMC Oral Health. 2021. PMID: 34006261 Free PMC article.
-
Isoprenoid geranylgeraniol: the influence on cell characteristics of endothelial progenitor cells after bisphosphonate therapy in vitro.Clin Oral Investig. 2015 Sep;19(7):1625-33. doi: 10.1007/s00784-014-1394-z. Epub 2015 Jan 16. Clin Oral Investig. 2015. PMID: 25589370
-
In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes.Clin Oral Investig. 2015 Jan;19(1):139-48. doi: 10.1007/s00784-014-1219-0. Epub 2014 Mar 26. Clin Oral Investig. 2015. PMID: 24668343
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical